126 related articles for article (PubMed ID: 33409930)
1. The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0.
Kuten J; Dekalo S; Mintz I; Yossepowitch O; Mano R; Even-Sapir E
EJNMMI Res; 2021 Jan; 11(1):3. PubMed ID: 33409930
[TBL] [Abstract][Full Text] [Related]
2. Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.
Yin Y; Werner RA; Higuchi T; Lapa C; Pienta KJ; Pomper MG; Gorin MA; Rowe SP
J Nucl Med; 2019 Apr; 60(4):511-516. PubMed ID: 30190303
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Indeterminate skeletal and lymph node lesion on 18F PSMA 1007 PET/CT scanning: lessons from a review at 12 months with PSMA-RADS.
Bhoil A; Seshadri N; Vinjamuri S
Nucl Med Commun; 2022 Sep; 43(9):1034-1041. PubMed ID: 35833288
[TBL] [Abstract][Full Text] [Related]
5. Interobserver agreement of [
Derwael C; Lavergne O; Lovinfosse P; Nechifor V; Salvé M; Waltregny D; Hustinx R; Withofs N
EJNMMI Res; 2020 Feb; 10(1):15. PubMed ID: 32112230
[TBL] [Abstract][Full Text] [Related]
6. Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients.
Grawe F; Blom F; Winkelmann M; Burgard C; Schmid-Tannwald C; Unterrainer LM; Sheikh GT; Pfitzinger PL; Kazmierczak P; Cyran CC; Ricke J; Stief CG; Bartenstein P; Ruebenthaler J; Fabritius MP; Geyer T
Eur Radiol; 2024 Feb; 34(2):1157-1166. PubMed ID: 37624414
[TBL] [Abstract][Full Text] [Related]
7. Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer.
Khatri W; Chung HW; Werner RA; Leal JP; Pienta KJ; Lodge MA; Gorin MA; Pomper MG; Rowe SP
Diagnostics (Basel); 2021 Apr; 11(4):. PubMed ID: 33917238
[TBL] [Abstract][Full Text] [Related]
8.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
9. Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT.
Werner RA; Thackeray JT; Pomper MG; Bengel FM; Gorin MA; Derlin T; Rowe SP
J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31331016
[TBL] [Abstract][Full Text] [Related]
10. Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CT.
Mihatsch PW; Beissert M; Pomper MG; Bley TA; Seitz AK; Kübler H; Buck AK; Rowe SP; Serfling SE; Hartrampf PE; Werner RA
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053434
[TBL] [Abstract][Full Text] [Related]
11. The Value of
Madsen C; Østergren P; Haarmark C
Diagnostics (Basel); 2020 May; 10(6):. PubMed ID: 32481743
[TBL] [Abstract][Full Text] [Related]
12. Comparison of hybrid
Janssen JC; Meißner S; Woythal N; Prasad V; Brenner W; Diederichs G; Hamm B; Makowski MR
Eur Radiol; 2018 Feb; 28(2):610-619. PubMed ID: 28779400
[TBL] [Abstract][Full Text] [Related]
13. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
Kuten J; Mabjeesh NJ; Lerman H; Levine C; Barnes S; Even-Sapir E
Isr Med Assoc J; 2019 Feb; 21(2):100-104. PubMed ID: 30772960
[TBL] [Abstract][Full Text] [Related]
14. Gallium-68-prostate-specific membrane antigen (
van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.
Maurer T; Gschwend JE; Rauscher I; Souvatzoglou M; Haller B; Weirich G; Wester HJ; Heck M; Kübler H; Beer AJ; Schwaiger M; Eiber M
J Urol; 2016 May; 195(5):1436-1443. PubMed ID: 26682756
[TBL] [Abstract][Full Text] [Related]
16. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on
Werner RA; Bundschuh RA; Bundschuh L; Javadi MS; Leal JP; Higuchi T; Pienta KJ; Buck AK; Pomper MG; Gorin MA; Lapa C; Rowe SP
J Nucl Med; 2018 Dec; 59(12):1857-1864. PubMed ID: 30190304
[TBL] [Abstract][Full Text] [Related]
17. [
Hirmas N; Al-Ibraheem A; Herrmann K; Alsharif A; Muhsin H; Khader J; Al-Daghmin A; Salah S
Mol Imaging Biol; 2019 Jun; 21(3):574-581. PubMed ID: 30215174
[TBL] [Abstract][Full Text] [Related]
18. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
19. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Performance of [
Paymani Z; Rohringer T; Vali R; Loidl W; Alemohammad N; Geinitz H; Langsteger W; Beheshti M
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32708097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
